ORAGENICS INC (OGEN) - Dilution Analysis

10-K filing | 4.3M shares outstanding

S-3 filing: The company is filing an S-3 form to register a shelf offering of up to $100,000,000 in various securities, including common stock, warrants to purchase common stock, and units consisting of combinations of these securities.

10-Q filing | 4.2M shares outstanding

10-Q filing | 4.1M shares outstanding

8-K filing: Oragenics, Inc. completed a public offering of 660,000 shares of Series H Convertible Preferred Stock and warrants to purchase 660,000 additional shares of Preferred Stock, resulting in gross proceeds of approximately $16.5 million. ($16.5M proceeds)

S-1/A filing: This S-1/A filing describes exempt issuance of common stock and related securities for employee compensation, strategic transactions, and other purposes.

S-1 filing: The company is offering Series H Convertible Preferred Stock, warrants to purchase Series H Convertible Preferred Stock, and common stock issuable upon conversion of the preferred stock and warrants, with Dawson James Securities, Inc. acting as placement agent.

8-K filing: Stock split 1-for-30 | Outstanding: 21,475,289 → 715,843

10-Q filing | 21.5M shares outstanding

10-K filing | 21.5M shares outstanding

S-1/A filing: This S-1/A filing relates to a best efforts public offering of up to 15,151,515 units, each consisting of one share of common stock (or one Pre-Funded Warrant) and one common warrant, at an assumed price of $0.33 per unit, along with placement agent warrants.

S-1/A filing: Reasonable best efforts public offering of up to 15,151,515 units consisting of one share of common stock (or one Pre-Funded Warrant to purchase one share of our Common Stock in lieu thereof), and one common warrant to purchase one share of our Common Stock at an assumed public offering price of $0.33 per Unit.

S-1 filing: This is a reasonable best efforts public offering of up to 15,151,515 units consisting of one share of common stock and one common warrant at an assumed price of $0.33 per unit.

10-Q filing | 12.2M shares outstanding

8-K filing: Oragenics, Inc. completed a registered public offering of 3,078,378 shares of common stock and pre-funded warrants to purchase 5,028,206 shares of common stock, resulting in gross proceeds of approximately $4.45 million. ($0.0M proceeds)

S-1/A filing: This is an S-1/A filing for a public offering of up to 3,937,008 shares of common stock, up to 3,937,008 pre-funded warrants to purchase shares of common stock and up to 196,850 placement agent warrants to purchase shares of common stock.

S-1 filing: This is a reasonable best efforts public offering of up to 2,403,846 shares of our common stock at an assumed public offering price of $2.08 per share and also pre-funded warrants to purchase 2,403,846 shares of Common Stock.

10-Q filing | 5.6M shares outstanding

8-K filing: Oragenics, Inc. completed a registered public offering of 1,100,000 shares of common stock at $1.00 per share through a placement agency agreement with Dawson James Securities Inc., resulting in gross proceeds of approximately $1.1 million. ($1.1M proceeds)

10-Q filing | 4.5M shares outstanding

10-K filing | 4.5M shares outstanding

8-K filing: Oragenics acquired neurology assets from Odyssey Health, issuing 8,000,000 shares of Series F Non-Voting Convertible Preferred Stock, convertible into common stock on a one-to-one basis, and Odyssey converted 511,308 of those shares into common stock on December 28, 2023, in addition to $1,000,000 in cash.

8-K filing: Oragenics, Inc. authorized the issuance of 8,000,000 shares of Series F Convertible Preferred Stock for the acquisition of assets from Odyssey Health, Inc. ($1.0M proceeds)

10-Q filing | 2.4M shares outstanding

8-K filing: Oragenics, Inc. entered into an Asset Purchase Agreement with Odyssey Health, Inc. to purchase certain assets and liabilities related to Odyssey's business focused on developing medical products that treat brain related illnesses and diseases in exchange for $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock. ($1.0M proceeds)

8-K filing: Oragenics, Inc. completed the sale and transfer of certain materials and data to Lantern Bioworks in exchange for $50,000 in cash and an option to purchase 1,000,000 shares of Purchaser's equity for $1.00. ($0.0M proceeds)

10-Q filing | 2.5M shares outstanding

8-K filing: The company designates 404,728 shares of preferred stock as Series E Preferred Stock with no dividends, specific voting rights related to the Amendment, junior liquidation rights to Series A and B, and automatic cancellation upon the effectiveness of the Amendment. The company completed a private placement offering.

10-Q filing | 2.0M shares outstanding

10-K filing | 2.0M shares outstanding

8-K filing: Stock split 1-for-60 | Outstanding: 1,921,739 → 1,961,037

S-3 filing: The filing is an S-3 form for a potential offering of common stock, warrants to purchase shares of common stock, and/or units consisting of some or all of such securities for total gross proceeds of up to $40 million.

10-Q filing | 116.7M shares outstanding

10-Q filing | 116.4M shares outstanding

10-Q filing | 116.4M shares outstanding

10-K filing | 116.4M shares outstanding

10-Q filing | 116.4M shares outstanding

10-Q filing | 116.2M shares outstanding

10-Q filing | 91.8M shares outstanding

8-K filing: Oragenics, Inc. sold 15,406,618 shares of common stock for gross proceeds of approximately $20.0 million under a sales agreement as of February 12, 2021, and will file a prospectus supplement registering the offer and sale of common stock having an aggregate offering price of up to $17,462,500 from time to time through A.G.P. ($20.0M proceeds)

10-K filing | 46.1M shares outstanding

8-K filing: Oragenics, Inc. reports the redemption of Series C Preferred Stock, sales of common stock through an at-the-market offering, warrant exercises, and an update on common stock outstanding as of February 11, 2021. ($21.2M proceeds)

8-K filing: Oragenics, Inc. closed a registered direct offering of 14,444,444 shares of common stock, receiving gross proceeds of $6,500,000. ($6.5M proceeds)

8-K filing: Oragenics, Inc. issued 14,444,444 shares of common stock at $0.45 per share in a registered direct offering for gross proceeds of approximately $6,500,000. ($6.5M proceeds)

8-K filing: Oragenics, Inc. closed a public offering of 14,189,189 shares of common stock at $0.37 per share, with the Underwriter exercising their over-allotment option to purchase an additional 2,128,378 shares, resulting in gross proceeds of approximately $6.0 million. ($6.0M proceeds)

10-Q filing | 46.1M shares outstanding

10-Q filing | 46.1M shares outstanding

8-K filing: Oragenics Inc. announces the exercise of warrants to acquire 5,537,365 shares of common stock, resulting in gross proceeds of $5,058,628 and 60,900,168 shares of common stock outstanding. ($5.06M proceeds)

S-3 filing: Resale of up to 18,400,000 shares of common stock by selling stockholder, consisting of 9,200,000 restricted shares and 9,200,000 shares issuable upon exercise of warrants.

10-Q filing | 55.4M shares outstanding

8-K filing: Oragenics acquired Noachis Terra through a Stock Purchase Agreement, making it a wholly-owned subsidiary, focused on developing a vaccine product candidate to provide immunity from SARS-CoV-2. ($6.93M proceeds)

8-K filing: The Company acquired Noachis Terra by issuing 9,200,000 restricted shares of the Company's common stock and warrants to purchase 9,200,000 shares of the Company's common stock to Mr. Joseph Hernandez.

10-K filing | 46.1M shares outstanding